Compare Prospect Capital Corporation (PSEC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Sanofi SA — how do they compare? Prospect Capital Corporation trades at $1.83 (market cap $974.22M), while Sanofi SA trades at $40.02 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 97.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (23.01%). Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Sanofi SA for 94 Days on average.
| PSEC | SNY | |
|---|---|---|
Market Cap | $974.22M | $95.18B |
Volume | 5,779,996 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $3.05 | $52.34 |
52-Week Low | $1.82 | $39.51 |
Typical Hold Time | 78 Days | 94 Days |
Enterprise Value | $2.73B | $114.48B |
Dividend Yield | 23.01% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.84, up 0.55% with bearish technical signals despite recent earnings beats. The company shows inconsistent revenue trends with 2025 revenue at -$407M and net income of -$470M, though 2026 projections indicate recovery. Dividend payments continue at $0.04 monthly, while analyst sentiment remains mixed with 25% buy ratings amid concerns about NAV erosion and portfolio contraction.
PSEC presents high risk with volatile financial performance and bearish technical indicators. The 18%+ dividend yield appears unsustainable given negative cash flow and declining portfolio value. While current price represents a significant discount to book value, ongoing NAV erosion and mixed analyst consensus suggest cautious approach for investors seeking stability.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
